Researchers created a mobile cart device allowing people to communicate via laptops by eye movement alone. The device was designed with severely disabled tetraplegic patients in mind, but it may also help those with decreased upper extremity and hand function, like that caused by amyotrophic lateral sclerosis (ALS), to more easily work with a computer. Shannon…

In this video from Rare Disease Report, watch Dr. Shafeeq S. Ladha, from Barrow Neurological Institute in Phoenix, Arizona talk “about the numerous amyotrophic lateral sclerosis (ALS studies) they have underway at the institute.” Read the latest updates on ALS: https://bit.ly/ALSNewsToday…

Origent Data Sciences, Inc., and Cytokinetics, Inc., announced a new research partnership to further refine and validate an Origent computer model to predict the progression of amyotrophic lateral sclerosis (ALS) in patients — a progression that widely varies, making effective clinical trials difficult and costly — by leveraging data from previous and…

In this video from the Mayo Clinic, watch Dr. Leonard Petrucelli talk about how the clinic has been studying and researching for a new development of a mouse model “that exhibits the features linked with the most common genetic form of ALS and frontotemporal dementia.” Read…

AB Science announced that its Phase 2/3 clinical trial evaluating masitinib, the company’s lead compound to treat amyotrophic lateral sclerosis (ALS) patients, has met its primary objective. The ongoing study is currently recruiting participants and expects to finish in June 2017. “The positive outcome of this study in ALS is a significant milestone…

In this ALS Association video watch specialists in ALS care explore the choices available for respiratory support. Learn more about ALS here: https://bit.ly/ALSNewsToday ALS News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is…

Neuraltus Pharmaceuticals announced that it will initiate a second Phase 2 clinical trial of its investigational drug candidate NP001 for the treatment of amyotrophic lateral sclerosis (ALS), with the intent of confirming positive earlier findings in patients with elevated levels of baseline inflammation and further evaluating the drug’s efficacy. Inflammation is thought to be a…

Leaders in the field of induced pluripotent stem cell (iPSC) – a technology that can help derive motor neurons from people who suffer from amyotrophic lateral sclerosis (ALS) – have published a cutting-edge review, identifying advances and challenges in ALS modeling ability and calling for the development and adoption of rigorous criteria…

1. Herantis’ Potential ALS Treatment, CDNF, Recommended for Orphan Drug Status by EMA Herantis Pharma announced that it has received a positive opinion from the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) on…

In this cauchilab video, “Cyrielle Delmas meets graduate Rebecca Borg at her Dr. Cauchi’s lab at the University of Malta to talk about her research on ways to cure ALS/motor neuron disease.” Learn more about Borg’s research here: https://www.researchgate.net/profile/Rebecca_Borg2 Learn more about ALS here: https://bit.ly/ALSNewsToday…